GCG and type 2 diabetes mellitus: The limited familiarity of primary care physicians with incretin-based therapies can significantly impact accessibility to GLP-1 RAs, given that most people with type 2 diabetes are treated by primary care physicians rather than diabetologists or endocrinologists.